Medicina al día con el Dr. Echegaray MD.

22/10/2025

22/10/2025

19/10/2025

El sistema CAD-RADS™ 2.0, desarrollado por la SCCT, ACR y ACC, actualiza la forma de reportar la enfermedad arterial coronaria.
Evalúa tres pilares clave:
🔹 Grado de estenosis (0–5)
🔹 Carga de placa (P1–P4)
🔹 Modificadores → HRP (placa de alto riesgo), I (isquemia), S (stent), G (bypass), E (excepciones).

Su objetivo: hablar el mismo idioma entre radiólogos y cardiólogos, mejorar la comunicación y optimizar el manejo del paciente.

💡 Imagen: segmentación coronaria con las principales arterias analizadas en CCTA.

30/12/2023

🎄 La absorción de está influenciada por diferentes , como la insulina, el glucagón, la colecistoquinina, el péptido similar al glucagón tipo 1 (GLP-1) y otras .

Conoce más sobre la absorción de los nutrientes en el tracto gastrointestinal con esta infografía que hemos preparado para ti.

Aprende más en 📲 https://ow.ly/luEt50Qm01x

: El lugar donde médicos, profesionales de la salud y pacientes pueden entrar.

30/12/2023

Darwin Alvarado

New nomenclature and diagnostic criteria for fatty liver disease agreed by global consensus

The term "steatotic liver disease" was chosen to encompass various causes of steatosis, while the name chosen to replace NAFLD was "metabolic dysfunction–associated steatotic liver disease" (MASLD). The diagnostic criteria were also updated to include the presence of at least one of five cardiometabolic risk factors. Additionally, a new category called "metabolic and alcohol-related/associated liver disease (MetALD)" was introduced for individuals with MASLD who consume higher amounts of alcohol.

The new nomenclature and criteria are considered non-stigmatizing and have widespread support, with potential benefits for awareness and patient identification.

Full text here: https://bit.ly/3NSPgme


EASL - The Home of Hepatology

30/12/2023

A major research gap: The use of anticoagulants in cirrhosis

Historically, anticoagulants were contraindicated in patients with cirrhosis owing to concerns about bleeding risks. However, recent studies have shown that patients with cirrhosis are not naturally anticoagulated and are at increased risk of prothrombotic events, such as portal venous thrombosis. In this article, we review preclinical and clinical data on the effects of anticoagulants in cirrhosis, including their potential benefits in reducing liver fibrosis, portal hypertension, and improving survival. Despite promising preclinical evidence, clinical translation has proven challenging. Nevertheless, we discuss the use of anticoagulation in specific clinical scenarios, such as patients with atrial fibrillation and portal vein thrombosis, and highlight the need for further research, including randomised-controlled trials, to determine the optimal role of anticoagulants in the management of patients with cirrhosis.

Expert Opinion by Marco Senzolo and Juan Carlos Garcia-Pagan

Full text here: www.journal-of-hepatology.eu/article/S0168-8278(23)00407-5/fulltext


EASL - The Home of Hepatology